<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767221</url>
  </required_header>
  <id_info>
    <org_study_id>U-03-003</org_study_id>
    <nct_id>NCT00767221</nct_id>
  </id_info>
  <brief_title>Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study</brief_title>
  <official_title>Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calliditas Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archimedes Development Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Calliditas Therapeutics AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effect of PL-56 on albumin leakage and renal function&#xD;
      (glomerular filtration rate) in patients with IgA nephropathy. It will also assess the safety&#xD;
      of treatment with PL-56.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>U-albumin</measure>
    <time_frame>6(treatment)+3(follow-up) months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR and safety</measure>
    <time_frame>6(treatment) + 3(follow-up) months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient is his own control. Endpoint variables are measured before, during and after treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>8 mg PL-56 once daily for six months</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Nefecon, PL-56 (topical acting, anti-inflammatory agent)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Female or male patient &gt; 18 years&#xD;
&#xD;
          -  Biopsy-verified IgA nephropathy&#xD;
&#xD;
          -  Proteinuria: U-albumin &gt;500 mg/24 h&#xD;
&#xD;
          -  S-creatinine &lt; 200 umol/L&#xD;
&#xD;
          -  A minimum of four available sample results (U-albumin and S-creatinine) prior to&#xD;
             inclusion in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe gastrointestinal disorders which may impair drug effect, or other conditions&#xD;
             which could modify the effect of the trial drug as judged by the investigator&#xD;
&#xD;
          -  Consumption of an investigational drug within 30 days prior to enrolment&#xD;
&#xD;
          -  Unacceptable blood pressure (treated or untreated), defined as a systolic value &gt;150&#xD;
             mm Hg and/or diastolic &gt;90 mm Hg&#xD;
&#xD;
          -  Hyperlipidaemia defined as unacceptable levels of lipids according to the discretion&#xD;
             of the Investigator&#xD;
&#xD;
          -  Patients in whom an ACE inhibitor was introduced/changed during the last three months&#xD;
             prior to enrolment&#xD;
&#xD;
          -  Patients treated with immuno-suppressive drugs&#xD;
&#xD;
          -  Patients unable to take oral medication&#xD;
&#xD;
          -  Severe liver disease (defined as ASAT and/or ALAT and/or gamma-GT above twice the&#xD;
             normal value).&#xD;
&#xD;
          -  Uncontrolled (treated or untreated) congestive heart failure as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Patients with diabetes&#xD;
&#xD;
          -  Patients with current malignancy or history of malignancy during the last three years&#xD;
&#xD;
          -  History or presence of psychological or psychiatric illness which may interfere with&#xD;
             the patient´s ability to adhere to the protocol&#xD;
&#xD;
          -  Alcohol or drug abuse (present)&#xD;
&#xD;
          -  Patients unwilling to meet the requirements of the protocol&#xD;
&#xD;
          -  Other medical or social reasons for exclusion at the discretion of the Investigator&#xD;
&#xD;
          -  Use of drugs inhibiting the cytochrome P-450 enzyme CYP3A4 (including grape fruit&#xD;
             juice)&#xD;
&#xD;
          -  Kidney transplanted patients&#xD;
&#xD;
          -  For women only: pregnant or breast feeding; unwilling to use adequate contraception&#xD;
             during the study (only women of childbearing potential)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Fellström, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital, Dept. of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huddinge University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>October 5, 2008</study_first_submitted>
  <study_first_submitted_qc>October 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>April 20, 2009</last_update_submitted>
  <last_update_submitted_qc>April 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Johan Häggblad</name_title>
    <organization>Pharmalink AB</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

